Raltegravir Inclusion Decreases CD4 T-Cells Intra-Cellular Viral Load and Increases CD4 and CD28 Positive T-Cells in Selected HIV Patients

Raltegravir (RLT) prevents the integration of HIV DNA in the nucleus, but published studies remain controversial, suggesting that it does not decrease proviral DNA. However, there are only a few studies focused on virus-targeted cells. We aimed our study on the impact of RLT inclusion on total intra...

Descripción completa

Detalles Bibliográficos
Autores principales: Kumar, Gaurav, Cottalorda-Dufayard, Jacqueline, Garraffo, Rodolphe, De Salvador-Guillouët, Francine, Cua, Eric, Roger, Pierre-Marie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8773801/
https://www.ncbi.nlm.nih.gov/pubmed/35053324
http://dx.doi.org/10.3390/cells11020208

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8773801/
https://www.ncbi.nlm.nih.gov/pubmed/35053324
http://dx.doi.org/10.3390/cells11020208

Ejemplares similares